https://ojs.bbwpublisher.com/index.php/DH/issue/feedDermatological Health2025-07-11T14:40:50+08:00Open Journal Systems<p style="text-align: justify;"><em>Dermatological Health</em> is a peer-reviewed, open access journal that publishes original research articles and review articles related to the prevention, diagnosis, and treatment of disorders of the skin, hair, and nails. The covered topics include, but are not limited to: clinical, investigative, and population-based studies, healthcare delivery and quality of care research, high quality, cost effective, and innovative treatments, new diagnostic techniques, and other topics related to the prevention, diagnosis, and treatment of disorders of the skin, hair, and nails. Each issue includes continuing medical education articles designed to fill practice and knowledge gaps in the delivery of dermatologic care. </p>https://ojs.bbwpublisher.com/index.php/DH/article/view/11133Validation of the Reliability and Validity of PSAQCSD, a Psychosocial Adaptation Assessment for Patients with Chronic Urticaria2025-07-11T14:40:50+08:00Song Liteam@bbwpublisher.comAijun Chenteam@bbwpublisher.com<p><em>Objective</em>: This study aims to verify the reliability and validity of the Chinese version of the Psychosocial Adaptation Questionnaire (PSAQ-CSD) in patients with chronic urticaria (CU), to assess their psychosocial adaptation levels. <em>Methods</em>: The study involved 102 confirmed cases of chronic urticaria. The PSAQ-CSD was translated and culturally adapted for Chinese use, followed by a pre-survey validation. Exploratory factor analysis and Cronbach’s α coefficient were used to test the construct validity, internal consistency reliability, and criterion-related validity of the scale. <em>Results</em>: The Cronbach’s α coefficient for the Chinese version of the PSAQ-CSD was 0.930, indicating good internal consistency. Exploratory factor analysis showed a KMO value of 0.848 and a cumulative variance contribution rate of 65.142%, consistent with the original scale structure. Criterion-related validity analysis revealed strong correlations between the PSAQ-CSD and the CU-Q2oL scale in emotional, self-cognitive, and social dimensions. All correlations were statistically significant, <em>P</em> < 0.05. <em>Conclusion</em>: The Chinese version of the PSAQ-CSD demonstrates good reliability and validity in patients with chronic urticaria, making it an effective tool for assessing psychosocial adaptation. It can comprehensively reflect patients’ emotional states, self-cognition, and social adaptation, providing a theoretical basis for clinical intervention and psychological support. Future research should expand the sample size and consider more cultural and social factors to enhance the application range and accuracy of the scale.</p>2025-07-11T14:33:26+08:00Copyright (c) 2025 Author(s)https://ojs.bbwpublisher.com/index.php/DH/article/view/11136Real-World Study on Adverse Reactions to Technetium (Tc99m) Medronate Based on VigiAccess Database Mining2025-07-11T14:40:48+08:00Weigang Liuteam@bbwpublisher.comQian Wuteam@bbwpublisher.comHeqing Tanglwgtjmu001@outlook.com<p><em>Objective: </em>This study aims to explore adverse events related to Technetium (Tc99m) Medronate using the VigiAccess database, uncover potential risk signals, and provide comprehensive reference for rational clinical drug use to ensure patient safety. <em>Methods: </em>The study retrieved adverse event reports related to Technetium (Tc99m) Medronate from the VigiAccess database, preprocessed the data, and employed the Reporting Odds Ratio (ROR) method to detect signals and analyze the characteristics and intensity of adverse events. <em>Results:</em> A total of 543 adverse event reports related to Technetium (Tc99m) Medronate were retrieved. The data showed that reports from female patients accounted for 48.62%, higher than the 26.15% from male patients, and the 18–64 age group had a higher proportion of reports at 52.89%. In terms of adverse event distribution, skin and subcutaneous tissue disorders accounted for 24.12%, general disorders and administration site conditions accounted for 21.68%, and nervous system disorders accounted for 14.83%. These three types of disorders were the most common adverse reactions during the use of Technetium (Tc99m) Medronate. Further ROR analysis revealed strong associations between Technetium (Tc99m) Medronate and adverse events such as product efficacy issues, vasodilation, and decreased therapeutic response. The ROR value for product efficacy issues was as high as 379.29 (95% CI: 180.18, 798.47), vasodilation was 60.75 (95% CI: 45.91, 80.51), and decreased therapeutic response was 36.35 (95% CI: 20.48, 64.81). <em>Conclusion:</em> This study analyzed adverse events related to Technetium (Tc99m) Medronate using the VigiAccess database, finding that female patients and the age group of 18 to 64 had a higher proportion. The related adverse events were mainly concentrated in skin and subcutaneous tissue disorders, general disorders and administration site conditions, and nervous system disorders. Adverse events such as product efficacy issues, vasodilation, and decreased therapeutic response were strongly associated with Technetium (Tc99m) Medronate, indicating the need for special attention to these adverse reactions in clinical use, strengthening drug monitoring and management to ensure patient safety, and providing important reference for clinicians in the rational use of Technetium (Tc99m) Medronate.</p>2025-07-11T14:40:12+08:00Copyright (c) 2025 Author(s)